Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shukra PharmaceuticalsBOM:524632 -1.63%71 Pretax Margin % is 6.03% as of Mar. 2026, which is 60% below its 10-year median of 15.26. GuruFocus rates BOM:524632 with a GF Score™ of 71/100 and a GF Value™ of ₹8.67 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Shukra Pharmaceuticals ranks better than 97.61% on this metric.
The historical rank and industry rank for Shukra Pharmaceuticals's Pretax Margin % or its related term are showing as below:
BOM:524632'
s Pretax Margin % Range Over the Past 10 Years
Min: 0.87 Med: 15.26 Max: 50.75
Current: 50.74
BOM:524632's Pretax Margin % is ranked better than 97.61% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs BOM:524632: 50.74
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Shukra Pharmaceuticals Pretax Margin % Related Terms
Shukra Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Shukra Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524632 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shukra Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Shukra Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shukra Pharmaceuticals (BOM:524632) has a Pretax Margin % of 6.03% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shukra Pharmaceuticals and its competitors. This is 60% below median its historical median of 15.26. Over the past decade, Shukra Pharmaceuticals' Pretax Margin % has ranged from 0.87 to 50.75. According to the industry distribution chart, Shukra Pharmaceuticals ranks #23 out of 961 companies in the Drug Manufacturers industry, placing it in the top 2.4%.
Is Shukra Pharmaceuticals' Pretax Margin % too high?
Shukra Pharmaceuticals' current Pretax Margin % of 6.03% is 60% below median its 10-year median of 15.26. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 50.75. The Drug Manufacturers industry median Pretax Margin % is 7.28. Shukra Pharmaceuticals' value of 6.03% is 17.2% below this industry median. Based on the distribution chart, Shukra Pharmaceuticals ranks #23 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shukra Pharmaceuticals has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shukra Pharmaceuticals ranks #23 out of 961 companies for Pretax Margin %. This places Shukra Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Shukra Pharmaceuticals' value of 6.03% is 17.2% below this benchmark. Historically, Shukra Pharmaceuticals' own Pretax Margin % has ranged from 0.87 to 50.75 over the past decade. While the company's 10-year median is 15.26 vs. the industry median of 7.28, Shukra Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shukra Pharmaceuticals's current Pretax Margin % of 6.03% is 17.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shukra Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shukra Pharmaceuticals's current Pretax Margin % is 6.03%, which is 60% below median its own 10-year median of 15.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.67, compared to a current price of ₹33.89 — trading 290.9% above its estimated fair value. The current Pretax Margin % is 6.03%, which is 60% below median its 10-year median of 15.26 and 17.2% below the Drug Manufacturers industry median of 7.28. Shukra Pharmaceuticals' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current Pretax Margin % is 6.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?
Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹33.89 is trading 290.9% above its estimated GF Value™ of ₹8.67.
GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:524632:
Pretax Margin %: 6.03% (60% below median its 10-year median of 15.26)
GF Value™: ₹8.67 vs. price of ₹33.89 (290.9% above fair value)
Industry Position: 17.2% below the Drug Manufacturers median (#23 of 961)
No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
71GF Score
Get the complete analysis for BOM:524632
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524632 has been successfully added to your 
